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ABSTRACT

EXAMINATION OF CD133 AND CD147 AS CANCER STEM CELL MARKERS

By
Christopher McMahon

To date, as many as 14,000 patients in the United States per year are diagnosed
with glioblastoma, the most common and most malignant primary brain tumor.
Glioblastomas are characterized by their ability to evade treatment on many fronts, thus a
novel approach to curative therapies is imperative. A population of cells with stem celllike properties are found within glioblastoma tumors and drive their initiation and
progression. Identification of extracellular markers on these tumor stem cells is thus
paramount. The cell surface glycoproteins CD133 and CD147 were examined as potential
markers of cancer stem cells found in glioblastoma. Here we found evidence which
shows that formation of neurospheres with U87MG glioblastoma cells may be driven by
increased expression of CD147, correlated with increased CD133 expression. These
findings suggest that relative levels of CD147 expression may be used as a determinant to
target cancer stem cells in glioblastoma.
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INTRODUCTION

Glioblastoma (GBM) is the most prevalent central nervous system-borne primary
brain tumor found in adults. They are typically exceedingly aggressive tumors; 90% of
patients die within three years and half fail to see a second year1. What is equally
problematic is that they are also exceedingly difficult to treat. Surgery, and modern
chemotherapy and radiotherapy are largely unsuccessful. Patients are also largely at risk
for recurrent tumors2.
What is currently highly regarded as the theory behind GBM tumors’ resistance to
treatment is the cancer stem cell theory. This theory proposes that within a GBM tumor
there are different tumorigenic phenotypes; one of these phenotypically-different cells is
capable, if transplanted into a host, of generating new tumors. This type of cell is referred
to as a cancer stem cell (CSC) because of its similarity to normal stem cells3. The CSC
theory postulates that this small subpopulation of cancer cells drives tumor growth; of
any given GBM tumor, only 1-30% of the total cell volume is comprised of CSCs4. As
they exhibit characteristics of normal stem cells, they are potentially able to differentiate
into neuronal, astroglial, and oligodendroglial cells; the resulting tumor will
characteristically be a mixture of cell types2-3.
The majority of primary neurological tumors in adults are glial-cell derived, and
of those, GBM are the most prevalent. Despite their prevalence, there are few treatment
options. This is due largely to a multifaceted approach of GBMs to thwart attempts to
combat it. GBM tumor cells alter adjacent normal cells to facilitate growth of tumor
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cells, invasion, resistance to chemical treatment, evasion of immune attack, and
metastasis1-3. And while the human immune system can typically initially retard tumor
growth, it is often thwarted by immunosuppressive pathways activated by tumor cells3.
It has also been shown that non-CSCs may have the ability to revert back to CSCs
under particular environmental cues5; CSC traits may be acquired via the epithelial to
mesenchymal transition (EMT). Through this process, (differentiated) epithelial cells can
assume the mesenchymal phenotype, to wit: the ability to migrate, invade, and resist
apoptosis6. Thus, even benign tumor cells may eventually exhibit invasiveness and
metastatic potential. It seems then that GBM cells may simply be classified into CSCs
and “not-as-yet CSCs”. Therefore, removing even 99% of the mass of a typical GBM
tumor and subsequently treating the remaining mass of cells with chemo- and
radiotherapy is scarcely a guarantee of success; the <1% that remains could certainly
possess the ability to regrow the tumor, metastasize, etc. It is thus paramount that we be
able to identify and target what is constitutively a CSC.
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LITERATURE REVIEW

CD133

GBMs, or Grade IV astrocytomas, are highly proliferative and heterogeneous
tumors which have proven quite difficult to treat. This work will first examine the
potential for the transmembrane glycoprotein CD133 to be a hallmark of human
glioblastoma CSCs. CD133, also referred to as Prominin-1, is a 5-transmembrane
glycoprotein of 117 kDa encoded by a gene on chromosome 4p15. It is expressed by
hematopoietic progenitor cells, embryonic stem cells, and various cancers7.
While it is thought to be responsible for orchestrating cell-cell topography, neither
its ligands nor its actual function are certain8. However, cells expressing CD133 have
been shown to have self-renewing and differentiating ability in vivo; it has been used to
identify putative cancer stem cell populations from malignant brain tumors, as well as
other types of cancers9.
However, CD133- CSCs have also been isolated and shown to form tumors10. It is
possible that these cells harbored an occult population of expressed CD133 protein that
wasn’t realized, perhaps because of differential folding resulting from differential
glycosylation masking specific CD133 epitopes11. This makes detection of expressed
CD133 using antibodies difficult; it suggests the possibility that what is described as a
CD133- population is actually a population of cells that is CD133+ but with differing
glycosylation status12. In addition, difficulty in identifying the CD133 molecule could
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also be due to local tumor microenvironment13, or epigenetic modifications, such as
promoter methylation14. What is also problematic is that the majority of CD133+ cells are
characterized by having significantly higher levels of expression of O6-methylguanineDNA-methyltransferase, or MGMT, compared to CD133- cells 15. MGMT is a DNA
repair protein and is the chief antagonist to Temozolomide (TMZ), the most frequently
employed antitumor alkylating agent. Methylation of the MGMT promoter has been
shown to both increase chemosensitivity to alkylating agents16,17 and to correlate with an
improved response to radiotherapy18. Thus, cells with higher levels of CD133 correlate
with antitumor drug resistence19, and resistance to radiotherapy15.
Therefore, the evidence points to CD133+ cells being a hallmark of GBM CSCs.

CD147

While the role of CD133 is unclear, the CD147 molecule (basigin) has been well
described. CD147 is a 385-amino acid molecule with a molecular weight of 42 kDa
found on the surface of many types of cells, including leukocytes, epithelial and
endothelial cells. It is an integral membrane protein belonging to the immunoglobulin
superfamily of proteins, and as such plays an essential role in intercellular recognition20.
CD147 is also highly glycosylated giving the protein an apparent MW of around 60 kDa.
Additionally, CD147 regulates the expression of the monocarboxylate transporter (MCT)
family of proteins. MCTs are responsible for shuttling lactic acid out of highly malignant
tumors which rely on anaerobic glycolysis as an energy source21; without MCTs the
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resulting buildup of lactate would acidify the cell cytoplasm and slow or stop cellular
metabolism.
One of the best-described functions of CD147 is its ability to induce expression of
matrix metalloproteinases (MMP) in stromal cells22. It is from this function that its
alternate name, EMMPRIN (Extracellular Matrix MetalloPRoteinase Inducer), is derived.
Matrix metalloproteinases are from a large family of proteins and have many differing
functions, but we are chiefly concerned with their pathophysiologic functions, such as
modulation of tumor microenvironment. In this capacity MMPs are essential for cell
growth, angiogenesis, inflammation, and tumor cell migration23. Thus, CD147 induces
expression of molecules which support tumor growth and increase lethality and
aggressiveness of tumors. Under the relatively-hypoxic conditions, the conditions
employed in this study, CD147 promotes tumor growth, enhances tumor malignancy, and
inhibits tumor cell apoptotic ability24.
CD147 up-regulates MMP secretion by adjacent stromal cells, which in turn
degrade the extracellular matrix. Thus, CD147 is a key element in tumor invasion,
metastasis, and progression.25. It has been shown that CD147 is overexpressed on the
surface of GBMs, and further, that relative level of CD147 expression is correlated with
WHO grade of astrocytoma26. These findings suggest that CD147 is a worthwhile
therapeutic target.
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Hypoxia

Currently, GBM tumors are treated by surgical removal and subsequent treatment
with both chemotherapy and radiotherapy. One agent mitigating the effects of these latter
two treatments is intratumoral hypoxia27. TMZ, the most-used anti-GBM drug, has been
found to target only GBM cells derived from the peripheral layer of the tumor mass28.
The interior-most cells, the cells exposed to the least amount of circulating oxygen, have
proven the most resistant to the alkylating agent treatment. These data suggest that there
is a direct correlation between intratumoral hypoxic gradient and resistance of the tumor
cells to chemotherapeutic agents.
In normal brain tissue, physiological concentrations of oxygen will vary between
0.5 and 7.5%. In GBM tissue, however, this value is markedly decreased to as little as
0.1% or less29, suggesting hypoxia is an agent of GBM. The hypoxic microenvironment
plays a key role in the regulation of the CSC phenotype; exposure of GBM cells to
hypoxic conditions encouraged a phenotypic shift of cells toward a more stem-like state,
and these alterations were in turn accompanied by upregulation of markers of
undifferentiated cells, such as Oct4, and neural stem cell markers, like nestin30.
Additionally, hypoxic culturing also induces a phenotypic shift to one of increased
glycolytic activity; the cells undergo a metabolic reprogramming which ultimately results
in acidification of the tumor microenvironment. This acidic environment induces
upregulation of stem-cell genes such as VEGF31, and Olig2, Oct4, and Nanog32. Thus,
hypoxia induces phenotypic shifts towards stemness.
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Objectives

The literature suggests that the respective relative overexpression of CD133 and
CD147 antigen causes increased tumorigenicity. We examined this potential property
through direct comparison of high- and low-expressing cells of each antigen. The aim of
this work was to isolate a subpopulation of CD133+ human GBM cells and measure their
ability to form neurospheres in stem cell-culture suspension. In parallel, populations of
cells expressing various levels of CD147 were isolated to measure similar properties.
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EXPERIMENTAL DESIGN

Subculture of Human GBM Cell lines

LN229, T98, and U87MG adherent cell lines (American Tissue Culture
Collection, Manassas, VA) were removed from cryostasis in liquid nitrogen and
resuscitated. Per standard culturing methods, the T98 and U87MG lines were cultured in
Eagle’s Modified Essential Medium (EMEM; Lonza, Walkersville, MD) with 10% Fetal
Bovine Serum (FBS; Atlanta Biological, Atlanta GA); the LN 229 in Dulbecco’s
Modified Eagle’s Medium (DMEM; GE Life Sciences, Logan, UT) with added 5% FBS
(Atlanta Biological). Both media were supplemented with 1% Penicillin-StreptomycinAmphotericin B (PSA; Gibco, Carlsbad, CA) antibiotics. Cells were kept in cryostorage
in 1ml aliquots in freeze medium (90% FBS, 10% DMSO); each aliquot was added to
19ml of appropriate, pre-warmed complete culture medium in 75cm2 tissue-treated
culture flasks under laminar flow. Each was placed in incubation at 37⁰ C and 5% CO2
until near-confluency (~75%) was reached, at which point the respective flasks were
either passaged (subcultured) or cells were harvested for use. After one passage for each
cell line, cells were then transferred to 175cm2 flasks to increase total number of cells
available for RNA extraction and cell sorting. Cells were then kept in 175cm2 flasks
throughout the duration of the experiments.
To create a microenvironment which would potentially cause a phenotypic shift
towards a more stem cell-like state, after several passages, the cells were transferred from
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normoxic conditions to the hypoxic (5% CO2, 5% O2) incubator en masse and remained
there throughout the remainder of the study.

Extraction of mRNA

Once near-confluency had been achieved, cells were removed from respective
flasks with trypsin-versene (Lonza) and pelleted at 300 rcf for 10 minutes. RNA was
extracted from each cell line independently using an RNA/DNA/Protein AllPrep kit
(Qiagen, Valencia, CA) following manufacturer’s protocol. Pelleted cells had
supernatants removed and pellets were resuspended in 350µl Buffer RLT, and vortexed
several seconds to mix. Lysates were then homogenized using centrifugation at 14000
rpm (top speed) for 2 minutes using a tabletop centrifuge in conjunction with
QiaShredder (Qiagen, Valencia, CA) spin columns. After, lysates were transferred to
Allprep DNA spin column placed in 2ml collection tube and centrifuged at top speed 30
seconds. The flow through from each sample was then combined with 250µl 100%
ethanol and mixed by pipetting. Samples were then added to separate RNeasy spin
columns in a 2ml centrifuge tube and centrifuged at top speed 15 seconds. To each
column 700µl Buffer RW1 was added, and each tube centrifuged at top speed for 15
seconds. After, 500µl Buffer RPE was added to each column and centrifuged at top speed
for 15 seconds. This step was then repeated but centrifuged for 2 minutes to ensure
complete drying of the column. Columns were then removed and replaced in 1.5ml
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collection tubes. To each, 10µl of RNase-free H2O was added, and the columns were then
centrifuged at top speed for 1 minute.
If reverse transcription was not performed immediately after extraction, RNA
was stored at -20⁰C. Storage at -20⁰C was limited to one week or less.

Reverse Transcription

To convert the extracted RNA into cDNA, reverse transcription was performed
using avian myeloblastosis virus reverse transcriptase (AMV-RT) and the manufacturer’s
protocol (Promega, Madison, WI). Exactly 2µg of RNA was combined with 2µl of either
oligo dT primers (Promega, Madison, WI) or random hexamer primers (Promega,
Madison, WI). The amount in microliters varied and depended upon concentration of
RNA extracted from respective cell lysates; volumes did not exceed 8µl as total volume
of primer/RNA cannot exceed 11µl and the ratio of primer to template RNA cannot be
altered. Solutions containing oligo dT primers were incubated at 42⁰C and those
containing random hexamer primers were incubated at 37⁰C at a ratio of 0.5µg primer/µg
RNA in a sterile, nuclease-free 200µl microcentrifuge tube. This mixture was placed in a
Thermal Cycler (BioRad T100, BioRad, Hercules, CA) and heated to 70⁰C for 5 minutes,
then chilled to 4⁰C for 5 minutes. After, the primer/template mixture was kept on ice, and
the following were added in order:
5µl AMV RT 5X Reaction Buffer
2.5µl dNTP Mix
30 units AMV RT (at 10 units/µl; 3µl AMV RT added)
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dH2O sufficient to bring total volume to 25µl (amount varies depending upon
volume of RNA added)
The samples were then incubated for 60 minutes at the appropriate temperature
described earlier. The cDNA products were stored at -20⁰C for later use, if not used
immediately.

PCR

The cDNA obtained via reverse transcription was used to amplify the CD133
gene using endpoint PCR. Thermal Cycling parameters were in accordance with the PCR
Master Mix protocol (Promega, Madison, WI). Reactions of 25µl were set up as follows:
12.5µl PCR Master Mix (Promega)
10.0µl Nuclease-free H2O
1.25µl of each primer (forward and reverse)
2.25µl cDNA template
Parameters for the PCR amplification were as follows:
2 minutes at 95⁰C
1 minute at 51⁰C (5⁰C less than lowest Tm of primers)
1 minute at 72⁰C (optimal temperature for Taq polymerase)
This cycle was repeated a total of 35 times, after which a final extension of 5 minutes at
72⁰C was performed. After, samples were cooled to 4⁰C and examined immediately or
placed at -20⁰C until analyzed. Storage at -20⁰C was limited to one week or less.
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PCR Primer Design

Primer sets used were designed using Primer3 on My Biology Workbench
(http://workbench.sdsc.edu/). PrimerBlast was employed subsequently to ensure
specificity to target genes, and finally the IDT OligoAnalyzer tool (www.idtna.com) was
used to ensure favorable annealing to target sets and to preclude formation of primerdimers.

Table 1. IDT primer sets used for endpoint PCR and qPCR

Primer (Human)
CD133(1) forward
CD133(1) reverse
CD133(2) forward
CD133(2) reverse
CD133(3) forward
CD133(3) reverse
Basigin-2 forward
Basigin-2 reverse
GAPDH forward
GAPDH reverse

Sequence (5′-3′)
GTC CTG GGG CTG CTG TTT AT
TCC TTG ATC GCT GTT GCC AT
CCT GGT CCA ACA GGG CTA TC
GAA GGA CTC GTT GCT GGT GA
GCC AGC CTC AGA CAG AAA AC
CCA AGC CTT AGG AGC ATC TG
GCG GTT GGA GGT TGT AGG AC
GGG AGG AAG ACG CAG GAG TA
AAG GTC GGA GTC AAC GGA TTT
GGT
AGT GAT GGC ATG GAC TGT GGT
CAT

Gel Electrophoresis

A 1% agarose gel electrophoresis was subsequently used to detect for the
presence of DNA products synthesized during endpoint PCR. The gel was created by
combining 0.25g agarose and 25ml TBE (Tris/Borate/EDTA) buffer and heated until
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agarose dissolved. After cool enough to touch, 1µl 10µg/µl ethidium bromide was added
and mixed. Mixture was poured into standard gel box setup. PCR products were added
and run at 120V for 45 minutes in 1X TBE buffer. Gel bands were visualized using Gel
Doc Imaging System (BioRad, Hercules, CA).

Fluorescence Activated Cell Sorting (FACS)

Culture cells were evaluated for CD133 or CD147 expression using the S3 Cell
Sorter (BioRad, Hercules, CA).
For the CD133 FACS, the culture cells (LN 229, T98, and U87MG) were first
removed from the respective culture flasks with 8ml trypsin-versene (Lonza) or Accutase
(Innovative Cell Technologies, San Diego, CA) and resuspended in 16ml complete
medium. The respective cell suspensions were then centrifuged at 800 rcf for 5 minutes.
Supernatants were aspirated and pellets were resuspended in 2ml sort buffer [1X Ca/Mg
free PBS (Fisher Scientific, Pittsburgh, PA), 1% BSA (HyClone, Logan, UT), 25mM
HEPES (HyClone, Logan, UT), pH 7.0] and centrifuged as before. Supernatant was
aspirated and pellet resuspended in 120µl sort buffer. A 20µl sample of the cell
suspension was removed for use as a control sample. To the remaining 100µl of cell
suspension, 10µl of CD133 antibody (AC133-Viobright FITC, Miltenyi Biotec, San
Diego CA) was added in dark conditions. The mixture was allowed to incubate in
darkness at 4⁰C for 10 minutes, according to the manufacturer’s suggestion. Following
incubation, sample was centrifuged at 300 rcf for 5 minutes, supernatant removed, and
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pellet resuspended in 1ml sort buffer. This volume was increased to 4ml with sort buffer,
and control sample volume increased to 1ml with the same. Both samples were separately
strained twice using a 40µm cell strainer.
For the CD147 FACS, U87MG cells were removed from flasks using trypsinversene, resuspended in the same medium as above. The cells were then centrifuged at
850 rcf for 6 minutes. The supernatant was aspirated and pellets resuspended in 1.5ml
sort buffer and centrifuged as before. Supernatant was removed and pellets resuspended
in 100µl sort buffer. A 10µl sample was removed for use as a control sample. To the
remaining 90µl, 20µl of anti-CD147 reagent was added (MEM-M6/1) FITC Mouse mAb;
Novus Biologicals, Littleton, CO). The sample was then incubated at 4⁰C for 60 minutes
in darkness. Following incubation, samples were centrifuged at 400 rcf for 5 minutes.
Supernatants were removed and pellets resuspended in 1.2ml sort buffer, then
recentrifuged as before. This step was performed twice. Supernatants were then aspirated,
and pellets resuspended in 1ml sort buffer. Working samples and control samples were
brought to 4ml and 1ml volumes respectively with sort buffer and strained twice as
above.
In either case, before FACS the control samples were run through the sorter to
acquire fluorescence data for the untreated cells as a basis for comparison with the
fluorescent antibody-labeled cells. Once a standard had been established, new data were
acquired on the treated cells and a new standard established; unlabeled and antibodylabeled cells were then sorted and collected based on this standard, using the ProSort v1.2
Software (BioRad, Hercules, CA).
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Cells sorted for CD133 expression were sorted based on fluorescence to any
degree. This value is measured by the FACS instrument via photon emission. Unlabeled
cells simply pass by the laser in the instrument and emit no photons, thus no signal will
be detected. As fluorescent antibody-labeled cells pass by the laser, photons are emitted
and the intensity of the voltage measured by the instrument increases. These data are
displayed in the form of histograms, which plot a single parameter (i.e. FITC intensity, xaxis) against event number (y-axis); and scatter-plots, which plot two parameters
simultaneously: side-scatter intensity (y-axis) against fluorescence intensity (x-axis), with
each dot representing a single event. The x-axis shows relative fluorescence on a
logarithmic scale, with each successive “decade” representing a relative tenfold increase
in measured fluorescence. After antibody labelling, data were acquired on 100,000
events. On the resulting histograms, sorting gates were placed to collect the lowest-20%
fluorescing and highest-20% fluorescing cells in each sample; this percentage is indicated
numerically in the “statistics” window of the histogram plots.
Using these parameters, CD147 expression was divided into two groups: lowest20% expression (“low expression”) and highest-20% expression (“high expression”).

Subculture of Sorted Fractions

The U87 cells labeled with anti-CD147 antibody were sorted into “high” and
“low” fractions; the “low” fraction consisted of the 20% lowest-fluorescing (and
therefore, lowest-CD147-expressing) cells in the sample. The “high” fraction consisted of
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the 20% highest-fluorescing. From either fraction, 300,000 cells were placed in adherent
culture (FBS-supplemented medium) and same number of each placed in suspension
culture using complete stem cell medium [DMEM/F-12 with L-glutamine (Gibco,
Carlsbad, CA), 2% StemPro Neural Supplement (SPNS; Gibco), 20% Epidermal Growth
Factor (EGF; Preprotech, Rocky Hill, NJ), 20% Basic Fibroblast Growth Factor (bFGF;
Preprotech, Rocky Hill, NJ), 10mg/ml Gentimicin (Gibco), 0.5% PSA (Gibco), 0.5mg/ml
BSA (HyClone, Logan, UT)]. In both cases, 25cm2 flasks were used, each containing 4ml
of appropriate medium. After 96 hours of incubation in hypoxic conditions at 37⁰C,
cultures were observed for relative level of proliferation, neurosphere formation
(suspension culture) or total cell count (adherent culture).
For counting the adherent cells, cells were treated with 2 ml trypsin-versene
solution and allowed to incubate in hypoxia for 3 minutes, after which each flask was
placed back into the laminar flow hood and gently scraped for 30 seconds to remove any
remaining adhered cells. To this cell/trypsin solution, 6ml of EMEM complete medium
was added. After mixing by pipetting, the respective cell solutions were removed and
placed into 15ml conical tubes for cell counting. To a 100µl sample of each, Trypan Blue
dye was added at 1:6 dilution and cells were counted using a hemocytometer and
standard protocol.
Additionally, a subsequent sort was performed collecting the highest- and lowest1% CD147-expressing cells. These fractions were used exclusively for qualitative
examination using a confocal microscope.

16

Real-Time PCR Analysis of Sorted Fractions

U87MG cells were sorted into high- and low-fluorescing fractions as described.
Respective fractions were combined in conical tubes and centrifuged at 300 rcf for 10
minutes. Supernatants were aspirated, and RNA was extracted, reverse transcription
performed as described above. The cDNA obtained was amplified employing qPCR
using a LightCycler 2.0 (Roche Diagnostics, Indianapolis, IN). For this analysis, CD133,
CD147, and GAPDH genes were examined, the last being used as a control. This
instrument employs colorless glass capillary tubes and a carousel; each tube houses 20µl
of sample.
To the negative controls, 16µl PCR-grade H2O was added, followed by 2µl of
primers and 2µl LightCycler DNA Master SYBR Green I reagent (Roche Diagnostics,
Indianapolis, IN). After, 14µl of PCR-grade H2O was added, followed by 2µl of primers
and 2µl of SYBR Green I reagent, to separate thin-walled PCR tubes kept on ice. The
samples were mixed by pipetting, and then transferred to the capillary tubes contained
within centrifuge adapters, themselves contained within a cold block. All samples were
then centrifuged 30 seconds at 500g before being added to the LightCycler. The qPCR
was run using the following parameters:
Denaturation: 1 Cycle, 95⁰C, 30 seconds
Amplification: 45 Cycles: Denaturation: 95⁰C, 0 seconds
Annealing: 51⁰C, 5 seconds
Extension: 72⁰C, 30 seconds
Cooling: 1 Cycle, 40⁰C, 30 seconds
The data were analyzed using proprietary LightCycler software v. 4.05 (Roche
Diagnostics, Indianapolis, IN).
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Immunocytochemistry Analysis of CD133 Antibody using HF2303 Cancer Stem
Cells

Qualitative analysis of the anti-CD133 antibody (Miltenyi, San Diego, CA) was
performed using a confocal microscope (Olympus Fluoview FV1000 Confocal Laser
Scanning Microscope, FV10-ASW 3.1 software; Olympus Corporation Americas, Center
Valley, PA). HF2303 primary human GBM cancer stem cells (Henry Ford Hospital,
Detroit, MI) were cultured at 37⁰C in hypoxia using complete stem cell medium
[DMEM/F-12 with L-glutamine (Gibco, Carlsbad, CA), 2% StemPro Neural Supplement
(SPNS; Gibco), 20% Epidermal Growth Factor (EGF; Preprotech, Rocky Hill, NJ), 20%
Basic Fibroblast Growth Factor (bFGF; Preprotech, Rocky Hill, NJ), 10mg/ml
Gentimicin (Gibco), 0.5% PSA (Gibco), 0.5mg/ml BSA (HyClone, Logan, UT)]. 10ml of
medium (with suspended cells) was removed and placed in a 15ml conical tube. This was
centrifuged at 150rcf for 90 seconds. Then 9.4ml of the supernatant was aspirated,
leaving 0.6ml supernatant and HF2303 cells. The cells were resuspended and divided,
and 300µl was added to each well of one gasketed coverslip (CultureWell MultiWell
Chambered Coverslips, Grace Bio Labs, Bend, OR).
Coverslip wells were pretreated by adding 100µl Poly-d-Lysine (BD Biosciences,
San Jose, CA) to each well. After 10 minutes, the Poly-d-Lysine was removed and then
the cell suspension was added. The cells were allowed to incubate on the coverslip 6
hours at 37⁰C in hypoxia. After, the wells were removed of medium and washed twice
with 1X PBS. Then 400µl blocking buffer (5% BSA, 0.1% Triton X-100 in PBS) was
added and allowed to incubate under laminar flow for 20 minutes at RT. In a darkroom
under red safe light, 400µl of anti-CD133 antibody was added (1:1000) and allowed to
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incubate in darkness at room temperature for 60 minutes. The antibody solution was then
removed and wells were washed twice with wash buffer. This was removed and 400µl
4% paraformaldehyde solution was added and allowed to incubate for 20 minutes at RT.
Wells were then washed twice with 1X PBS. PBS was then removed, silicon gaskets
removed, and coverslips gently waved to air-dry. One drop per well of ProLong Diamond
Antifade Mountant with DAPI (ThermoFisher Scientific, Waltham, MA) and coverslips
were then mounted to slides. Slides were wrapped in foil and allowed to stand at RT
overnight (>12 hours).

Immunocytochemistry Analysis of High and Low CD147-expressing U87MG Cells

Further qualitative analyses of the sorted U87MG cells was performed using a
confocal microscope (Olympus Fluoview FV1000 Confocal Laser Scanning Microscope,
FV10-ASW 3.1 software; Olympus Corporation Americas, Center Valley, PA). The
slides were manufactured using gasketed coverslips as before (CultureWell MultiWell
Chambered Coverslips, Grace Bio Labs, Bend, OR). Two slides were made using
U87MG cells sorted based on relative expression of CD147. The first contained the
highest- and lowest-20% of CD147-expressing cells, and the second slide contained the
highest- and lowest-1% of CD147-expressing cells.
Of each cell type, 10,000 were added to a different coverslip well, which were
pretreated with Poly-D-Lysine (BD Biosciences, San Jose, CA) as described above. The
gasketed coverslips were allowed to incubate 6 hours at 37⁰C in hypoxia. After, 400µl of
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4% paraformaldehyde in PBS were added and allowed to incubate for 20 minutes at RT.
Wells were then washed twice with 1X PBS. PBS was then removed, silicon gaskets
removed, and coverslips gently waved to air-dry. One drop per well of ProLong Diamond
Antifade Mountant with DAPI (ThermoFisher Scientific, Waltham, MA) and coverslips
were then mounted to slides. Slides were wrapped in foil and allowed to stand at RT
overnight (>12 hours).

Statistical Analysis

Data obtained from adherent U87MG proliferation assay were expressed as mean
and standard error. Data were analyzed by paired two-tailed t-test; calculations were
performed using Microsoft Excel. Data were considered significant at P < 0.05.
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RESULTS

Identifying presence of CD133 transcripts in LN229, T98, and U87 cell lines

After RNA extraction, reverse transcription and subsequent endpoint PCR,
agarose gel electrophoresis was performed using the three CD133 primer sets to
determine the presence of CD133 DNA in the LN229, T98, and U87 cell lines. The
results indicate that the CD133 transcript is present in the cell lines and therefore could
be employed as a potential marker for cancer stem cells.
The data in figure 1 show bands present in lanes 4, 7, and 10 between 200-300bp
relative to the ladder; the product size for primer set 3 is 247bp which suggests the
presence of CD133 DNA across all three cell lines. Primer set 3 was used exclusively
henceforth due to its smaller size and ubiquity. A redundant agarose gel analysis was
subsequently performed (Figure 2), which confirms the success of this primer set.

Confocal Imaging of CD133 Protein Expression in Cancer Stem Cells

Because the literature indicates that levels of CD133 may be low among the
general population of GBM cells2,5,8,10-12, the antibody (CD133/1 (AC133) Viobright
FITC; Miltenyi Biotech, San Diego, CA) used to detect CD133 was tested on HF2303
cells which ubiquitously express the CD133 antigen33. The image shows almost complete
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binding of the antibody to the HF2303 cells, therefore suggesting the antibody indeed
binds to CD133 antigen (Fig. 3).

Identification of GBM Cells Positive for CD133

Using the methods described, the LN 229, T98 and U87MG cells were prelabeled with the FITC-conjugated anti-CD133 antibody and then sorted based on relative
fluorescence compared to unlabeled cells. Each sort yielded extremely low numbers of
cells which had shifted downstream far enough to be considered fluorescing; often these
numbers were two-figure or even single digit values. Commonly, ~0.03% of cells were
labelled by the antibody. Multiple sorts performed across all three cell lines yielded
similar results.
There is very little difference in either the histogram plots (Fig. 4-5) or the sidescatter plots (Fig. 6-7). Only several cells are displayed (Fig. 7) beyond the second
decade, where fluorescing cells would likely be, based on the fluorescence data acquired
before the antibody was introduced. These data indicate that while the cells were
expressing CD133 mRNA, CD133 could not be detected on the surface of the cell using
this method.

22

Sorting of U87MG Cells Based on Expression Levels of CD147

To ensure presence of CD147 on the target cells and successful binding of
antibody/fluorescence of FITC conjugate, U87MG cells were cultured overnight with
antibody and photographed using a fluorescent microscope. The data suggest the
presence of CD147 on the cell surface and that successful sorts may be performed using
these methods (Fig. 8).
U87MG cells were pre-labeled with anti-CD147 antibody with FITC conjugate
and sorted into high and low fractions. The initial sort yielded an identically-split
population; half the cells were expressing, half were not. Subsequent sorts found that
most cells were fluorescing relative to the unlabeled cells; about 99% on average. While
the cells displayed little or no expression of CD133, they exhibited nearly universal
expression of CD147.
After the cells were incubated with the anti-CD147 antibody, a clear shift is
noticeable in the histogram plot (Fig. 9-10). In the initial plot, the fluorescence peak
(representing presence of cells) is contained almost entirely within the first decade of the
area log. After antibody addition, roughly 90% of the fluorescence peak is located
beyond the first decade, indicating a significant increase in the level of fluorescence
relative to the unlabeled U87MG cells. Therefore, a vast majority of the cells expressed
the CD147 antigen.
In similar fashion, the scatterplots of the pre- and post-antibody-labeled U87MG
cells display a clear downstream shift in the cell concentration (Fig. 11-12). Blue areas
indicate the areas of highest cell concentration. After the U87MG cells were labelled with
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the anti-CD147 antibody, the cell population had clearly exhibited a tenfold increase in
level of fluorescence relative to the unlabeled U87MG cells. Thus, a majority of the
U87MG cells tested were bound by antibody, indicating presence of CD147 on a vast
majority of the cells.

Cells with Increased CD147 Expression Form Neurospheres in Suspension Culture

After sorting into fractions, collected high- and low-CD147-expressing U87MG
cells were collected and placed into suspension culture using complete stem cell medium.
The cells were placed in hypoxia at 37⁰C and allowed to remain for four days. After 96
hours incubation time, the culture flasks were photographed using a light microscope.
This was repeated two additional times, for a total of three groups of (high and low)
expression culture (Fig. 13-18). The cells expressing the higher levels of CD147 had
formed large neurospheres after incubating 96 hours in hypoxia. In the cultures of cells
expressing relatively low CD147 levels, no neurospheres had formed. The suspension
cultures of low-expressing CD147 remained as singlet cells; there were only rare
instances of even doublets formed by these cells.

Adherent Cultures of High-CD147 Cells are More Proliferative

Fractions of U87MG cells expressing both high and low levels of CD147 (20%
highest-expressing/20% lowest-expressing) were also separately added to adherent cell
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culture and allowed to proliferate. After 96 hours, cells were counted using standard
manual methods. To preclude bias, identity of respective flasks was hidden and revealed
to the author after results were tallied. In all three sets of cultures, the U87MG cells
expressing relatively higher levels of CD147 were more proliferative (Figure 19). The
mean values for each group were calculated. The mean concentration of cells in the highexpressing group was 4.245 million cells/ml; in the low-expressing group this value was
1.665 million cells/ml. Thus, the high-expressing group showed a 245% increased growth
rate compared to the low-expressing group of U87MG cells.

qPCR Data Suggest Increased CD147 Levels and Increased CD133 Levels are
Correlated

CD133 and CD147 gene expression was assessed by qPCR. ΔCT levels were
recorded for CD133 and CD147 relative to GAPDH. The ΔCTs for the CD147 levels in
the high and low fractions were 8.38 and 6.67, respectively, for a positive ΔΔCT of 1.71.
While it is interesting that the low-CD sample had a slightly lower CT, these values
indicate strongly positive reactions with abundant CD147 gene expression. The values
also indicate relatively high levels of CD147 in general, relative to the CT of GAPDH.
The respective ΔCTs in the high-CD147 (ΔCT=16.86) and the low-CD147 (ΔCT=19.79)
samples of CD133 were also strongly positive, suggesting relatively high levels of
CD133 gene expression in both samples. The ΔΔCT for these samples is 2.93, with an
expression fold change of 7.62. Thus, CD133 was expressed 7.62 times more in the highCD147 sample compared to the low-CD147 sample. These data indicate that CD133
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gene expression is present in U87MG cells, and that high-CD147 levels may strongly
correlate with elevated expression of CD133.

Laser Confocal Imaging of Sort Fractions Confirms Expected CD147 Levels Based
On Sort Parameters

Cells from either high or low sort fractions were added to gasketed coverslips,
fixed with 4% paraformaldehyde, and mounted to slides using DAPI-containing
mounting medium. The U87MG cells expressing highest levels of CD147 all exhibit
green coloration (FITC, attached to anti-CD147 antibody) at areas close to but distinctly
separate from the cell nuclei (Blue, DAPI-stained) (Fig. 20). Because the highest-20%
fraction fluoresce at high levels per the sort data, the cells collected in the higher
expressing fraction of U87MG cells should all be labelled with FITC; the confocal
images suggest the same.
Conversely, we expect that the low CD147-expressing fraction of U87MG cells
collected would have some FITC expression visible under microscopy, though not all.
Based on fluorescence data from sorting, the low population does include U87MG cells
that either do not express surface CD147 or express at low enough levels that the
fluorescence was not detected. Lastly, the low population would include cells which
simply did not bind antibody for any reason. Some low CD147-expressing cells certainly
express CD147, based on FITC fluorescence. Other U87MG appeared to express little
CD147. Yet other labelled U87MG cells appeared to be expressing no CD147 whatever,
or at least did not appear to fluoresce (Fig. 21).
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To streamline this approach relative to this experiment, microscope slides were
prepared with the highest- and lowest-1% fractions from FACS and U87MG cells labeled
with the same anti-CD147 antibody as described. The highest 1% population exhibits
universal basigin expression as indicated by the green fluorescence (FITC) (Fig. 22).
None of the cells in the lowest-1% fraction are exhibiting any detectable levels of
fluorescence, suggesting that isolating these two extreme populations for study is possible
(Fig. 23).
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DISCUSSION

While it has been shown that stem-like cancer cells may be cultured successfully
using adherent or suspension conditions35,37, and that U87MG cells form neurospheres in
suspension culture36-37, a correlation between U87MG/GBM neurosphere formation and
CD147 levels may be a novel finding. We have shown here that U87MG GBM cells
expressing relatively high levels of CD147 on the cell surface are both more proliferative
and more likely to form neurospheres than their lower-expressing counterparts. All three
suspension cultures of U87MG cells expressing high levels of CD147 formed large
neurospheres in culture after only four days, and none of the cells expressing low levels
of CD147 formed neurospheres after the same time period. These data suggest that
CD147 levels are directly correlated with neurosphere formation in GBM cells, or that
the CD147 levels are indicative of some other such agent of neurosphere formation.
We attempted to show that CD147 is a cancer stem cell marker in order to
establish it as a worthwhile target for antitumor therapy. The evidence presented here has
validated our attempts. Because CD147 is not typically found on glial cells and neurons,
it can be employed to delineate normal, healthy tissue from cancerous tissue.
Chemotherapeutic agents targeting CD147 would not only be a highly effective form of
treatment, but targeting this population of cells would not affect healthy tissue
surrounding the tumor mass, bypassing a major hurdle confronted during surgical
excision.
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Preliminary data recorded performing qPCR on the high and low sort fractions
suggests that CD133 overexpression on U87MG cells is correlated with CD147
overexpression. While this was preliminary data performed from cDNA collected from a
single sort and must be confirmed and reconfirmed, CD147 overexpression may
positively affect CD133+ CSC enrichment. It is possible that the cells are geared toward
expressing relatively high levels of the CD133 antigen but epigenetic factors and
posttranslational modifications prevent this expression from being realized14. Because
inhibition of the Sonic Hedgehog pathway in CD133+ cells enhances the effectiveness of
the chemotherapeutic agent temozolomide37, identifying this population of cells based on
CD147 expression would be quite effective.
RNA extraction and subsequent reverse transcription and endpoint PCR indicate
that the transcripts for CD133 are present among all three GBM cell lines used
throughout these experiments. Therefore it was expected that sorting LN229, T98, and
U87MG cells based on relative levels of CD133 antigen expression should be possible. It
is not clear that the GBM cell lines do not express the CD133 antigen. It is possible that
the trypsin-versene and Accutase used to remove the cells from the culture flask may
cleave the AC133 epitope, which may require a longer period of time devoted to cell
recovery before the addition of antibody. While the manufacturer of the antibody
(Miltenyi) insists that 10 minutes is sufficient time for antibody binding, it may be
prudent to increase the incubation time, which may improve binding. This approach will
also help address any issues regarding recovery period of the epitope following
trypsinization/collagenization with Accutase. Non-enzymatic removal of the cells from
the flask seemed like a logical alternative to treatment with proteinase or collagenase and
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may leave the CD133 antigen intact. However this removal method was not deemed
viable as it was impossible to separate the cells, which is necessary for sorting.
Furthermore, as stated earlier it has been suggested11 that the CD133 antigen may
be expressed on the cell surface, but precluded from binding to the antibody due to steric
hindrance or similar problems. However, the correlation suggested by these data indicates
that by selecting for a population of U87MG cells expressing increased levels of CD147
we also enrich a population of CD133+ cells. Thus, it would certainly be possible to sort a
high-CD147 population of U87MG cells and in turn label those cells with the anti-CD133
antibody. This approach should significantly increase the percentage of CD133+ cells
while also precluding any problems like steric hindrance of antibody binding, cleavage of
AC133 epitope, etc.

Future Directions

To confirm if CD147 expression is responsible for neurosphere formation and
adherent-cell proliferation as the data suggested here, it would be prudent to employ the
CRISPR Interference technique to repress CD147 expression. The Clustered regularly
interspaced short palindromic repeats (CRISPR) pathway is a genetic perturbation
technique which affords transcriptional-level sequence-specific activation or repression
of gene expression, similar to RNA Interference38. This technique can repress
transcription by blocking transcriptional initiation or elongation, or inducing
heterochromatization; it has been shown to generate gene knockouts in humans39. Thus,
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this technique could be used to knock out CD147 expression in U87MG cells. Then,
drawing on the correlation established here, these cells could be sorted based on relative
levels of CD133 expression; the CD133+ group would otherwise be identical to the highCD147 U87MG cells used here, save CD147 expression. These cells would then be
suspension-cultured as performed here and observed for neurosphere formation.
Secondly, to confirm or disconfirm the effects of hypoxia on CD147 expression/
neurosphere formation, the experiment should be repeated with U87MG cells incubated
only in normoxia. If neurospheres reform it might suggest that either the relative
expression levels of CD147 are not driven by environmental oxygen levels, or that the
levels of CD147 expressed in normoxia are sufficient to drive neurosphere formation,
assuming CD147 is indeed the agent of neurosphere formation herein. Repeating the
experiment in normoxia followed by CRISPR knockout of CD147 expression would
further illustrate the role CD147 plays in proliferation and formation of neurospheres in
U87MG cells. Additionally, once the experiment has been repeated and neurosphere
formation observed, the neurosphere assay should be performed to confirm the ability of
the cells in the neurosphere to proliferate and self-renew, and to assess their potency
level.
In conclusion, we have demonstrated here that U87MG cells can be sorted based
on relative levels of CD147 expression. We have shown that U87MG cells expressing
relatively high levels of CD147 will form neurospheres when incubated in suspension
culture in hypoxia. We have also shown that U87MG cells expressing high CD147 levels
are more proliferative in adherent culture than low-CD147 expressing U87MG cells. We
have also supplied preliminary data which may suggest CD147 overexpression and
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CD133 overexpression in U87MG cells are correlated, and it is possible that these two
conditions in conjunction cause increased proliferation and neurosphere formation. Thus,
CD147 and CD133 are worthwhile targets for GBM therapy going forward.
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Figure 1. Agarose gel electrophoresis analysis of LN229, T98, and U87MG PCR products using CD133
primers. Arrows indicate bands from Set 3 between 200-300bp.
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Figure 2. Comparison of LN229 and U87MG cells displaying bands after PCR performed with the three
CD133 primer sets. Primer set 3, in lane 9, displays dark band in 200-300bp range (arrow).
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Figure 3. HF2303 neurospheres express the stem cell marker CD133. Neurospheres stained with DAPI
(blue) and examined under confocal laser microscopy. Cells labelled with anti-CD133 antibody with FITC
conjugate (green).
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Figure 4. Fluorescence data of T98 cells before labelling with anti-CD133 antibody. Data acquired
using S3 sorter.

Figure 5. Fluorescence data of T98 cells after labelling with anti-CD133 antibody. Cells were
incubated 10 minutes at 4⁰C in darkness before data acquisition using S3 sorter.
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Figure 6. Scatterplot of T98 cells before labelling with anti-CD133 antibody.

Figure 7. Scatterplot of T98 cells after labelling with anti-CD133 antibody.
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Figure 8. U87MG cells express surface CD147. Cells were labeled with FITC-conjugated anti-CD147
antibody (indicated by green in figure).
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Figure 9. Histogram of U87MG cells before labelling with anti-CD147 antibody.

Figure 10. Fluorescent histogram of U87MG cells after labelling with anti-CD147 antibody. Blue
bars represent sorting gates; 20% lowest-expressing-basigin (R1) and 20% highest-expressingbasigin (R2) cells were collected
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Figure 11. Scatterplot of U87MG cells before anti-CD147 antibody addition. Blue/green area
indicates highest concentration of cells.

Figure 12. Scatterplot of U87MG cells after incubation with anti-CD147 antibody. Blue indicates
presence of highest concentration of cells.
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Figure 13. U87MG cells expressing high levels of CD147 form neurospheres in suspension culture. First
group of cells incubated at 37⁰C for 96 hours in hypoxic suspension culture. Image taken at 4X.
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Figure 14. U87MG cells expressing low levels of CD147 do not form neurospheres in suspension culture.
First group of cells incubated at 37⁰C for 96 hours in hypoxic suspension culture. Image taken at 4X.
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Figure 15. U87MG cells expressing high CD147 levels form neurospheres in suspension culture. Second
group of cells incubated at 37⁰C after 96 hours in hypoxic suspension culture. Image at 4X.
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Figure 16. U87MG cells expressing low CD147 levels do not form neurospheres in suspension culture.
Second group of cells incubated at 37⁰C after 96 hours in hypoxic suspension culture. Image at 4X.
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Figure 17. U87MG cells expressing high CD147 levels form neurospheres in suspension culture. Third
group of cells incubated at 37⁰C after 96 hours in hypoxic suspension culture. Image at 4X.
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Figure 18. U87MG cells expressing low CD147 levels do not form neurospheres in suspension culture.
Third group of cells incubated at 37⁰C after 96 hours in hypoxic suspension culture. Image at 4X.
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Figure 19. U87MG cells with increased CD147 expression are more proliferative. Comparison of relative
proliferation levels of High CD147-expressing vs. Low CD147-expressing adherent U87MG cells. Cells
were incubated 96 hours in hypoxia. Bars represent mean cell concentrations of three independent trials and
standard error.
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Figure 20. CD147 is expressed on U87MG cells. Laser Confocal Microscopy Image of U87MG cells
expressing 20%-highest levels of CD147. Cells stained with DAPI (blue), labelled with anti-CD147
antibody with FITC conjugate (green). Image taken at 10X.
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Figure 21. CD147 is absent on some U87MG cells. Laser Confocal Image of 20%-lowest-CD147expressing U87MG cells stained with DAPI (blue) and anti-CD147 antibody conjugated with FITC (green).
Image taken at 10X.
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Figure 22. CD147 is expressed on U87MG cells. U87MG cells stained with DAPI (blue) and labelled with
anti-CD147 antibody conjugated with FITC (green). Cells were among highest-1% CD147 expression.
Image at 20X.
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Figure 23. CD147 is not expressed on all U87MG cells. Laser confocal image shows lowest-1% of U87MG
cells expressing CD147. Nuclei are DAPI stained (blue), cells labelled with anti-CD147 antibody
conjugated with FITC. Image at 10X.
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